Provided by Tiger Fintech (Singapore) Pte. Ltd.

Vanda Pharmaceuticals

4.51
-0.0200-0.44%
Post-market: 4.510.00000.00%16:11 EDT
Volume:323.68K
Turnover:1.47M
Market Cap:265.79M
PE:-5.92
High:4.60
Open:4.57
Low:4.49
Close:4.53
Loading ...

Vanda Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
14 Feb

Vanda Pharmaceuticals targets total annual revenue in excess of $1B in 2030

TIPRANKS
·
14 Feb

Vanda Pharmaceuticals reports Q EPS (8c) vs. (4c) last year

TIPRANKS
·
14 Feb

Vanda: Q4 Earnings Snapshot

Associated Press Finance
·
14 Feb

Vanda Pharma Q4 EPS $(0.08) Beats $(0.11) Estimate, Sales $53.19M Beat $52.25M Estimate

Benzinga
·
14 Feb

Vanda Pharmaceuticals Inc: Q4 Total Revenues of $53.2 Mln

THOMSON REUTERS
·
14 Feb

BRIEF-Vanda Pharmaceuticals Q4 EPS USD -0.08

Reuters
·
14 Feb

Vanda Pharmaceuticals Q4 Net Income USD -4.912 Million

THOMSON REUTERS
·
14 Feb

Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

PR Newswire
·
14 Feb

Vanda Pharmaceuticals Inc expected to post a loss of 11 cents a share - Earnings Preview

Reuters
·
12 Feb

Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025

PR Newswire
·
06 Feb

Vanda Pharmaceuticals, AnaptysBio Sign Global License Agreement for Imsidolimab

MT Newswires Live
·
03 Feb

BRIEF-Vanda, Anaptys Bio Enter into Global Deal TO Develop & Market Imsidolimab

Reuters
·
03 Feb

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an Il-36R Antagonist

THOMSON REUTERS
·
03 Feb

Vanda Pharmaceuticals Inc: Vanda Expects to Immediately Begin Preparing Bla and Maa Applications for US and EU

THOMSON REUTERS
·
03 Feb

Vanda Pharmaceuticals Inc: Anaptys to Receive $15 Mln From Vanda, Comprised of a $10 Mln Upfront Payment and $5 Mln for Existing Drug Supply

THOMSON REUTERS
·
03 Feb

Vanda Pharmaceuticals Inc: Anaptys to Receive a 10% Royalty on Global Net Sales of Imsidolimab

THOMSON REUTERS
·
03 Feb

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist

GlobeNewswire
·
03 Feb

Vanda Pharmaceuticals Inc expected to post a loss of 11 cents a share - Earnings Preview

Reuters
·
03 Feb

US retail investors dive into tech stocks in response to DeepSeek selloff

Reuters
·
31 Jan